ReviewJournal of cancer research and clinical oncology2026
Piezo channels in tumors.
Review in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
introductionMalignant tumors currently pose a significant threat to global health. Tumor progression is jointly regulated by genetic mutations and the mechanical properties of the tumor microenvironment (TME), including increased tissue stiffness, elevated fluid pressure, and mechanical compression experienced by circulating tumor cells (CTCs) within microvessels. These mechanical signals are transmitted through mechanosensitive pathways, with the Piezo channel family (Piezo1/Piezo2) serving as a core mediator.With their propeller-like trimeric structure, Piezo channels sense membrane tension, mediate calcium influx, and activate downstream signaling pathways (e.g., MAPK, PI3K/AKT/mTOR, YAP/TAZ), thereby regulating tumor cell proliferation, migration, immune microenvironment remodeling, and cancer stem cell-like transformation. Its expression exhibits tissue specificity and correlates with tumor staging, invasiveness, and pro gnosis.
resultsPiezo1 is upregulated in breast, esophageal, colorectal, glioma, and prostate cancers to promote tumor progression, while its downregulation in lung cancer enhances malignancy.Notably, the Piezo1 channel can be activated by mechanical compression in microcapillaries, subsequently promoting circulating tumor cells to acquire stem cell-like properties through calcium signaling pathways, thereby enhancing their metastatic potential. This discovery not only reveals the pivotal role of mechanical forces in tumor metastasis but also positions the Piezo channel as a promising biomarker for tumor diagnosis and prognostic assessment. Currently, targeted strategies for the Piezo channel-including small-molecule modulators and treatments based on piezoelectric materials-are gradually opening new avenues for precision cancer therapy, although issues such as tissue specificity of function and drug selectivity require further exploration.
conclusionOverall, as a vital bridge linking mechanical signals in the tumor microenvironment to cellular biological behavior, Piezo channels hold significant importance for deepening our understanding of tumor mechanisms, developing novel biomarkers, and optimizing therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.